Christopher Boerner, who will become CEO on 1 November, reported Q1 progress for new drugs Sotyktu, Camzyos and Opdualag, noting that greater growth for these early launches is still to come.
With many new drugs launched, now BMS must meet several big sales targets • Source: Shutterstock
Christopher Boerner will take over the CEO role at Bristol Myers Squibb Company on 1 November when Giovanni Caforio retires. And as he has done for the last several BMS earnings calls as chief commercialization officer, Boerner spent the company’s first quarter 2023 call on 27 April discussing new launches that will drive revenue growth as current blockbusters lose exclusivity. In some high-profile products’ cases, he pleaded for patience as those assets establish their commercial footing.
[Sidebar#SC148278]
Keep up with the top pharma business news of the week. On the go.
The big pharma CEO with the highest-valued compensation in 2024 was David Ricks of Eli Lilly, while Pfizer and J&J executives slipped into third and fourth place behind AbbVie's now retired chief Richard Gonzalez. European firms brought up the rear.
Amgen’s Imdelltra for small-cell lung cancer is one of two bispecific T-cell engagers approved for solid tumors, but data at the WCLC meeting show other DLL3-targeting BiTEs may be on the way.
An academic study of GLP-1 agonist showed promise in patients with the painful skin condition but with no signs that the Danish drugmaker will pursue the indication, smaller players in the space may be interested.
Starboard Value has reportedly bought a $1bn stake in Pfizer with an ambition to turn the big pharma around. But growth, not cost cuts, are Pfizer’s challenge.
<p>Executive Summary </p>
<br>
<p>Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements</p>